Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02492672 · ClinicalTrials.gov registry record
Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease
A clinical trial, sponsored by American Regent.
- Completed
- Registry status
- 50
- Enrollment target
NCT02492672: Completed study, sponsored by American Regent.
NCT02492672 is a clinical trial that has completed, run by American Regent. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02492672 has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The current registry is being undertaken to assess the long-term (12 month) safety and tolerability of Venofer in the pediatric population with chronic kidney disease that requires intravenous iron maintenance therapy.
Primary Outcome
Adverse Events starting from from the 1st dose of Venofer adminstered on study through 12 month observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-09 |
| Est. Completion | 2018-12 |
What the finished NCT02492672 record still lists
NCT02492672 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02492672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02492672 about?
NCT02492672 is a clinical study titled "Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease". The current registry is being undertaken to assess the long-term (12 month) safety and tolerability of Venofer in the pediatric population with chronic kidney disease that requires intravenous iron maintenance therapy.
What is the current status of trial NCT02492672?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2014-09. Estimated completion is 2018-12.
Who is sponsoring clinical trial NCT02492672?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia